Papers 10000
1 page of 1,000 pages (10k results)
#1Robert H. PressH-Index: 13
#2Arpit M. ChhabraH-Index: 8
Last. Charles B. Simone (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 50
view all 0 authors...
#1Caroline Chung (University of Texas MD Anderson Cancer Center)H-Index: 11
#2Paul D. Brown (Mayo Clinic)H-Index: 92
Last. Jeffrey S. Wefel (University of Texas MD Anderson Cancer Center)H-Index: 30
view all 0 authors...
#1Sophie H A E Derks (EUR: Erasmus University Rotterdam)
#2Joost L.M. Jongen (EUR: Erasmus University Rotterdam)H-Index: 13
Last. Astrid A.M. van der Veldt (EUR: Erasmus University Rotterdam)H-Index: 12
view all 0 authors...
#1Francesco Cicone (Magna Græcia University)H-Index: 1
Last. Giuseppe Minniti (UNISI: University of Siena)H-Index: 53
view all 0 authors...
#1Gi-Ming Wang (Case Western Reserve University)H-Index: 1
#2Gino CioffiH-Index: 6
Last. Justin D. Lathia (Cleveland Clinic Lerner Research Institute)H-Index: 61
view all 12 authors...
BACKGROUND Gliomas are the most common type of malignant brain and other CNS tumors, accounting for 80.8% of malignant primary brain and CNS tumors. They cause significant morbidity and mortality. This study investigates the intersection between age and sex to better understand variation of incidence and survival for glioma in the United States. METHODS Incidence data from 2000-2017 were obtained from CBTRUS, which obtains data from the NPCR and SEER, and survival data from the CDC's NPCR Regist...
#1Begoña Giménez-Cassina López (Brigham and Women's Hospital)H-Index: 11
#2Ishwar N. Kohale (MIT: Massachusetts Institute of Technology)H-Index: 2
Last. Michael S. Regan (Brigham and Women's Hospital)H-Index: 7
view all 28 authors...
BACKGROUND Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping drug distribution, target engagement, and adaptive response to gain insights into heterogeneous response to therapy. METHODS Patient derived xenograft (PDX) lines of glioblastoma were treated with adavosertib, a Wee-1 inhibitor, and tissue drug distri...
#1Jasmin Jo (ECU: East Carolina University)
#2Joseph Donahue (UVA: University of Virginia)H-Index: 7
Last. David Schiff (UVA: University of Virginia)H-Index: 73
view all 5 authors...
BACKGROUND Venous thromboembolism (VTE) occurs in up to 30% of patients with high-grade glioma (HGG). Concern for increased risk of intracranial hemorrhage (ICH) with therapeutic anticoagulation complicates VTE treatment. Some retrospective studies have reported an increased risk of ICH associated with therapeutic anticoagulation; however, effective alternatives to anticoagulation are lacking. The aim of our study is to assess the risk of ICH in HGG patients with VTE on low molecular weight hepa...
#1Jasper Wu (UCSF: University of California, San Francisco)H-Index: 1
#2Rohit Gupta (UCSF: University of California, San Francisco)H-Index: 24
Last. David A. Solomon (UCSF: University of California, San Francisco)H-Index: 37
view all 10 authors...
#1Nayan Lamba (Harvard University)H-Index: 12
#2Ayal A. Aizer (Brigham and Women's Hospital)H-Index: 34
#1Hua Huang (Science for Life Laboratory)H-Index: 7
#2Maria Georganaki (Science for Life Laboratory)H-Index: 7
Last. Fredrik Pontén (Science for Life Laboratory)H-Index: 77
view all 18 authors...
BACKGROUND Tumor vessels in glioma are molecularly and functionally abnormal, contributing to treatment resistance. Proteins differentially expressed in glioma vessels can change vessel phenotype and be targeted for therapy. ELTD1 (Adgrl4) is an orphan member of the adhesion G-protein-coupled receptor family upregulated in glioma vessels, and has been suggested as a potential therapeutic target. However, the role of ELTD1 in regulating vessel function in glioblastoma is poorly understood. METHOD...
Top fields of study
Cancer research